title: A pilot study of thalidomide for patients with symptomatic mesenteric panniculitis.
abstract: BACKGROUND
  Mesenteric panniculitis is a rare condition with no standard therapy.
  
  
  OBJECTIVE
  To assess the safety and efficacy of thalidomide for the treatment of patients with symptomatic mesenteric panniculitis using a newly established clinical disease activity index (Mesenteric Panniculitis Subjective Assessment Score).
  
  
  METHODS
  In an open-label pilot study, five patients with symptomatic mesenteric panniculitis received oral thalidomide, 200 mg nightly, for 12 weeks. The primary end-point was a reduction in the Mesenteric Panniculitis Subjective Assessment Score by > or = 20% at 12 weeks or complete remission (absence of symptoms).
  
  
  RESULTS
  Four (80%) of the five patients responded. The median Mesenteric Panniculitis Subjective Assessment Score at baseline was 39 and at week 12 was 25 (average decrease of 44%). One patient achieved complete remission by week 4, which was sustained. At 12 weeks, three (75%) patients experienced a global response, five (100%) patients had a > or = 20% (range, 29-98%) decrease in erythrocyte sedimentation rate and three (75%) patients had a > or = 20% (range, 61-93%) decrease in C-reactive protein. Abdomino-pelvic computed tomography scans were unchanged in all five patients. There were no serious adverse events.
  
  
  CONCLUSIONS
  Thalidomide is safe, well tolerated and efficacious in the treatment of some patients with symptomatic mesenteric panniculitis. Further study is indicated.
authors.affiliation: Division of Gastroenterology, Department of Medicine, University of Chicago Hospitals, Chicago, IL 60637, USA.
authors.forename: P M
authors.initials: PM
authors.lastname: Ginsburg
authors.forename: E D
authors.initials: ED
authors.lastname: Ehrenpreis
mesh_terms: D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015436:Panniculitis, Peritoneal / Q000097:blood / Q000188:drug therapy*; D010865:Pilot Projects; D011446:Prospective Studies; D012720:Severity of Illness Index; D013792:Thalidomide / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents; D013792:Thalidomide; D002097:C-Reactive Protein